Lamivudine Amarox

Lamivudine, the active ingredient in Lamivudine Amarox, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral tablet for oral use. It is used to treat human immunodeficiency virus (HIV) infection and chronic hepatitis B infection in adults and children as directed by a healthcare professional.

GNH USA supplies Lamivudine Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is an antiretroviral medication that targets viral replication in specific infections.

- HIV infection: reduces viral load and helps restore immune function when used in combination therapy. - Chronic hepatitis B infection: suppresses viral replication and improves liver function. - Prevention of mother‑to‑child transmission: lowers the risk of HIV transmission from pregnant women to their infants when part of a prescribed regimen.

Lamivudine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Fatigue: general tiredness. - Diarrhea: loose stools. - Insomnia: difficulty sleeping.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance. - Hepatotoxicity: liver enzyme elevations or failure. - Pancreatitis: inflammation of the pancreas. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic abnormalities: anemia or neutropenia.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters.

- Renal function: adjust dose if creatinine clearance is reduced. - Hepatic disease: monitor liver enzymes regularly. - Pregnancy and lactation: evaluate risk‑benefit ratio as safety data are limited. - Concomitant medications: review for potential drug‑drug interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Lamivudine can interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Tenofovir: potential additive renal toxicity. - Interferon‑alpha: may enhance hepatotoxic effects.

Moderate Interactions (Monitor Closely): - Rifampicin: may reduce lamivudine plasma levels. - Certain antacids: could affect absorption, monitor therapeutic response.